Arvinas, Inc. (NASDAQ:ARVN) CEO John G. Houston Sells 31,338 Shares

Arvinas, Inc. (NASDAQ:ARVN) CEO John G. Houston sold 31,338 shares of the firm’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $16.72, for a total transaction of $523,971.36. Following the completion of the sale, the chief executive officer now owns 1,157,480 shares of the company’s stock, valued at $19,353,065.60. This trade represents a 2.64 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Arvinas Trading Down 5.7 %

Shares of Arvinas stock opened at $16.75 on Tuesday. The firm’s 50-day moving average is $18.44 and its two-hundred day moving average is $22.85. Arvinas, Inc. has a 1 year low of $16.07 and a 1 year high of $51.51.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same quarter last year, the business earned ($2.53) EPS. Equities analysts expect that Arvinas, Inc. will post -3.81 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in ARVN. GF Fund Management CO. LTD. purchased a new stake in shares of Arvinas during the 4th quarter worth $28,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Arvinas by 0.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 433,531 shares of the company’s stock worth $8,311,000 after purchasing an additional 3,047 shares in the last quarter. Voloridge Investment Management LLC purchased a new stake in shares of Arvinas during the fourth quarter valued at about $749,000. Woodline Partners LP boosted its holdings in shares of Arvinas by 39.2% in the 4th quarter. Woodline Partners LP now owns 692,733 shares of the company’s stock valued at $13,280,000 after buying an additional 194,996 shares in the last quarter. Finally, Twinbeech Capital LP purchased a new position in shares of Arvinas in the 4th quarter worth approximately $3,146,000. 95.19% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ARVN. Oppenheimer increased their price objective on shares of Arvinas from $40.00 to $45.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 12th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arvinas in a report on Friday, February 7th. Guggenheim reiterated a “buy” rating and issued a $57.00 target price on shares of Arvinas in a research note on Wednesday, February 12th. BMO Capital Markets reiterated an “outperform” rating and set a $82.00 target price (down from $88.00) on shares of Arvinas in a research report on Wednesday, February 12th. Finally, Stephens started coverage on shares of Arvinas in a report on Monday, November 18th. They issued an “overweight” rating and a $55.00 price target on the stock. Twelve equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Arvinas currently has an average rating of “Buy” and a consensus target price of $60.00.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.